The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group".

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples